Wall Street analysts expect IDEXX Laboratories, Inc. (NASDAQ:IDXX) to announce $525.03 million in sales for the current fiscal quarter, according to Zacks. Four analysts have made estimates for IDEXX Laboratories’ earnings, with the lowest sales estimate coming in at $522.70 million and the highest estimate coming in at $527.53 million. IDEXX Laboratories posted sales of $462.02 million in the same quarter last year, which suggests a positive year-over-year growth rate of 13.6%. The firm is expected to issue its next earnings results before the market opens on Friday, May 4th.
On average, analysts expect that IDEXX Laboratories will report full-year sales of $2.22 billion for the current financial year, with estimates ranging from $2.20 billion to $2.23 billion. For the next year, analysts forecast that the business will report sales of $2.44 billion per share, with estimates ranging from $2.40 billion to $2.46 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for IDEXX Laboratories.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.04. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The company had revenue of $506.00 million during the quarter, compared to analyst estimates of $490.51 million. During the same quarter in the previous year, the business earned $0.58 EPS. The firm’s revenue was up 14.2% on a year-over-year basis.
In related news, Chairman Jonathan W. Ayers sold 36,000 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $179.28, for a total value of $6,454,080.00. Following the sale, the chairman now directly owns 1,077,112 shares of the company’s stock, valued at approximately $193,104,639.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Jonathan W. Ayers sold 22,000 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $177.52, for a total transaction of $3,905,440.00. Following the completion of the sale, the chairman now directly owns 1,077,112 shares in the company, valued at $191,208,922.24. The disclosure for this sale can be found here. Insiders sold a total of 71,576 shares of company stock worth $12,860,017 over the last ninety days. 2.56% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the business. Lombard Odier Asset Management Switzerland SA lifted its position in IDEXX Laboratories by 2.3% during the 4th quarter. Lombard Odier Asset Management Switzerland SA now owns 45,000 shares of the company’s stock worth $7,037,000 after buying an additional 1,000 shares in the last quarter. Atlantic Trust Group LLC bought a new stake in IDEXX Laboratories during the 3rd quarter worth about $65,381,000. Amalgamated Bank lifted its position in IDEXX Laboratories by 9.6% during the 4th quarter. Amalgamated Bank now owns 11,514 shares of the company’s stock worth $1,801,000 after buying an additional 1,006 shares in the last quarter. MANA Advisors LLC bought a new stake in IDEXX Laboratories during the 4th quarter worth about $413,000. Finally, Ontario Teachers Pension Plan Board lifted its position in IDEXX Laboratories by 35.7% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 9,746 shares of the company’s stock worth $1,524,000 after buying an additional 2,564 shares in the last quarter. 87.45% of the stock is currently owned by hedge funds and other institutional investors.
Shares of IDXX stock traded down $1.07 on Monday, hitting $196.75. The stock had a trading volume of 344,626 shares, compared to its average volume of 411,609. IDEXX Laboratories has a twelve month low of $146.09 and a twelve month high of $207.14. The firm has a market capitalization of $17,222.59, a price-to-earnings ratio of 59.98, a price-to-earnings-growth ratio of 2.42 and a beta of 0.59. The company has a quick ratio of 0.80, a current ratio of 0.97 and a debt-to-equity ratio of -11.26.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.